These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16115767)

  • 1. Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
    Chua PC; Nagasawa JY; Bleicher LS; Munoz B; Schweiger EJ; Tehrani L; Anderson JJ; Cramer M; Chung J; Green MD; King CD; Reyes-Manalo G; Cosford ND
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4589-93. PubMed ID: 16115767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists.
    Kamenecka TM; Bonnefous C; Govek S; Vernier JM; Hutchinson J; Chung J; Reyes-Manalo G; Anderson JJ
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4350-3. PubMed ID: 16039855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.
    Roppe JR; Wang B; Huang D; Tehrani L; Kamenecka T; Schweiger EJ; Anderson JJ; Brodkin J; Jiang X; Cramer M; Chung J; Reyes-Manalo G; Munoz B; Cosford ND
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3993-6. PubMed ID: 15225713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
    Tehrani LR; Smith ND; Huang D; Poon SF; Roppe JR; Seiders TJ; Chapman DF; Chung J; Cramer M; Cosford ND
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5061-4. PubMed ID: 16183275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.
    Büttelmann B; Peters JU; Ceccarelli S; Kolczewski S; Vieira E; Prinssen EP; Spooren W; Schuler F; Huwyler J; Porter RH; Jaeschke G
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1892-7. PubMed ID: 16439120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
    Bonnefous C; Vernier JM; Hutchinson JH; Chung J; Reyes-Manalo G; Kamenecka T
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1197-200. PubMed ID: 15686941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Huang D; Poon SF; Chapman DF; Chung J; Cramer M; Reger TS; Roppe JR; Tehrani L; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5473-6. PubMed ID: 15482906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
    Cosford ND; Tehrani L; Roppe J; Schweiger E; Smith ND; Anderson J; Bristow L; Brodkin J; Jiang X; McDonald I; Rao S; Washburn M; Varney MA
    J Med Chem; 2003 Jan; 46(2):204-6. PubMed ID: 12519057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists.
    Noeske T; Sasse BC; Stark H; Parsons CG; Weil T; Schneider G
    ChemMedChem; 2006 Oct; 1(10):1066-8. PubMed ID: 16986201
    [No Abstract]   [Full Text] [Related]  

  • 11. mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.
    Löscher W; Dekundy A; Nagel J; Danysz W; Parsons CG; Potschka H
    Neuropharmacology; 2006 Jun; 50(8):1006-15. PubMed ID: 16563443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia.
    Landucci E; Boscia F; Gerace E; Scartabelli T; Cozzi A; Moroni F; Mannaioni G; Pellegrini-Giampietro DE
    Int Rev Neurobiol; 2009; 85():337-50. PubMed ID: 19607979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity.
    Alagille D; Baldwin RM; Roth BL; Wroblewski JT; Grajkowska E; Tamagnan GD
    Bioorg Med Chem; 2005 Jan; 13(1):197-209. PubMed ID: 15582465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
    Roppe J; Smith ND; Huang D; Tehrani L; Wang B; Anderson J; Brodkin J; Chung J; Jiang X; King C; Munoz B; Varney MA; Prasit P; Cosford ND
    J Med Chem; 2004 Sep; 47(19):4645-8. PubMed ID: 15341479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Alkylated homoibotenic acid (HIBO) analogues: versatile pharmacological agents with diverse selectivity profiles towards metabotropic and ionotropic glutamate receptor subtypes.
    Madsen U; Pickering DS; Nielsen B; Bräuner-Osborne H
    Neuropharmacology; 2005; 49 Suppl 1():114-9. PubMed ID: 15996690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
    Smith ND; Poon SF; Huang D; Green M; King C; Tehrani L; Roppe JR; Chung J; Chapman DP; Cramer M; Cosford ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5481-4. PubMed ID: 15482908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists.
    Wendt JA; Deeter SD; Bove SE; Knauer CS; Brooker RM; Augelli-Szafran CE; Schwarz RD; Kinsora JJ; Kilgore KS
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5396-9. PubMed ID: 17723296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.
    Ito S; Satoh A; Nagatomi Y; Hirata Y; Suzuki G; Kimura T; Satow A; Maehara S; Hikichi H; Hata M; Kawamoto H; Ohta H
    Bioorg Med Chem; 2008 Nov; 16(22):9817-29. PubMed ID: 18849168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives.
    Noeske T; Jirgensons A; Starchenkovs I; Renner S; Jaunzeme I; Trifanova D; Hechenberger M; Bauer T; Kauss V; Parsons CG; Schneider G; Weil T
    ChemMedChem; 2007 Dec; 2(12):1763-73. PubMed ID: 17868161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure.
    Ceccarelli SM; Jaeschke G; Buettelmann B; Huwyler J; Kolczewski S; Peters JU; Prinssen E; Porter R; Spooren W; Vieira E
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1302-6. PubMed ID: 17189691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.